HUT72076A
(en)
*
|
1992-12-11 |
1996-03-28 |
Merck & Co Inc |
Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
|
US5492920A
(en)
*
|
1993-12-10 |
1996-02-20 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5494919A
(en)
*
|
1993-11-09 |
1996-02-27 |
Merck & Co., Inc. |
2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
US5492916A
(en)
*
|
1993-12-23 |
1996-02-20 |
Merck & Co., Inc. |
Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
WO1995014666A1
(en)
*
|
1993-11-24 |
1995-06-01 |
Merck & Co., Inc. |
Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s)
|
US5721251A
(en)
*
|
1993-12-10 |
1998-02-24 |
Merck & Co., Inc. |
Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
|
US5721250A
(en)
*
|
1993-12-23 |
1998-02-24 |
Merck & Co. Inc. |
Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
US5783582A
(en)
*
|
1994-07-20 |
1998-07-21 |
Merck & Co., Inc. |
Piperidines and hexahydro-1H-azepines spiro substituted at the 4-position promote release of growth hormone
|
US5656606A
(en)
*
|
1995-02-17 |
1997-08-12 |
Merck & Co., Inc. |
Camphor compounds promote release of growth hormone
|
US5731317A
(en)
*
|
1995-03-10 |
1998-03-24 |
Merck & Co., Inc. |
Bridged piperidines promote release of growth hormone
|
US5559128A
(en)
*
|
1995-04-18 |
1996-09-24 |
Merck & Co., Inc. |
3-substituted piperidines promote release of growth hormone
|
US5616571A
(en)
*
|
1995-06-06 |
1997-04-01 |
Merck & Co., Inc. |
Bisphosphonates prevent bone loss associated with immunosuppressive therapy
|
AU7169696A
(en)
*
|
1995-09-26 |
1997-04-17 |
Merck & Co., Inc. |
3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
|
EA199800337A1
(ru)
*
|
1995-10-27 |
1998-10-29 |
Мерк Энд Ко., Инк. |
Способ получения гормона роста, усиливающего секрецию
|
AU7522896A
(en)
*
|
1995-10-27 |
1997-05-15 |
Merck & Co., Inc. |
Wet granulation formulation of a growth hormone secretagogue
|
US5767124A
(en)
*
|
1995-10-27 |
1998-06-16 |
Merck & Co., Inc. |
Polymorphic forms of a growth hormone secretagogue
|
US6028196A
(en)
*
|
1995-10-27 |
2000-02-22 |
Merck & Co., Inc. |
Process for the preparation of a growth hormone secretagogue
|
WO1997022004A1
(en)
|
1995-12-13 |
1997-06-19 |
Merck & Co., Inc. |
Assays for growth hormone secretagogue receptors
|
US6531314B1
(en)
|
1996-12-10 |
2003-03-11 |
Merck & Co., Inc. |
Growth hormone secretagogue receptor family
|
GB2308362A
(en)
*
|
1995-12-19 |
1997-06-25 |
Lilly Industries Ltd |
Pharmaceutical indole derivatives
|
WO1997022367A1
(en)
*
|
1995-12-20 |
1997-06-26 |
Merck & Co., Inc. |
Radiolabeled growth hormone secretagogue
|
GB9601724D0
(en)
*
|
1996-01-29 |
1996-03-27 |
Merck Sharp & Dohme |
Therapeutic agents
|
HN1996000101A
(es)
|
1996-02-28 |
1997-06-26 |
Inc Pfizer |
Terapia combinada para la osteoporosis
|
WO1997034604A1
(en)
*
|
1996-03-21 |
1997-09-25 |
Merck & Co., Inc. |
4-spiroindoline piperidines promote release of growth hormone
|
GB9612276D0
(en)
*
|
1996-06-12 |
1996-08-14 |
Merck & Co Inc |
4-Spiroindoline piperidines promote release of growth hormone
|
US5804578A
(en)
*
|
1996-04-03 |
1998-09-08 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
|
WO1997041878A1
(en)
*
|
1996-05-07 |
1997-11-13 |
Merck & Co., Inc. |
Treatment of mood disorders with a growth hormone secretagogue
|
WO1997041879A1
(en)
*
|
1996-05-07 |
1997-11-13 |
Merck & Co., Inc. |
Enhancement of sleep with a growth hormone secretagogue
|
WO1998010653A1
(en)
*
|
1996-09-13 |
1998-03-19 |
Merck & Co., Inc. |
Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
|
US5877182A
(en)
*
|
1996-09-13 |
1999-03-02 |
Merck & Co., Inc. |
Piperidines promote release of growth hormone
|
US6046333A
(en)
*
|
1996-10-25 |
2000-04-04 |
Merck & Co., Inc. |
Convergent process for the preparation of a growth hormone secretagogue
|
EP0941115A1
(en)
*
|
1996-11-05 |
1999-09-15 |
Novo Nordisk A/S |
Use of growth hormone or a growth hormone secretagogue for promoting bone formation
|
AU5594398A
(en)
*
|
1996-12-09 |
1998-07-03 |
Merck & Co., Inc. |
Methods and compositions for preventing and treating bone loss
|
AU5803398A
(en)
*
|
1996-12-13 |
1998-07-03 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
US5962462A
(en)
*
|
1996-12-13 |
1999-10-05 |
Merck & Co., Inc. |
Spiro-substituted azacycles as modulators of chemokine receptor activity
|
UA59384C2
(uk)
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
WO1998046220A1
(en)
*
|
1997-04-14 |
1998-10-22 |
Merck & Co., Inc. |
Combination therapy for the prevention and treatment of osteoporosis
|
GB2324726A
(en)
*
|
1997-05-01 |
1998-11-04 |
Merck & Co Inc |
Combination Therapy for the Treatment of Osteoporosis
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
US6374762B1
(en)
*
|
1997-10-27 |
2002-04-23 |
Correct Craft, Inc. |
Water sport towing apparatus
|
US6117880A
(en)
*
|
1997-10-30 |
2000-09-12 |
Merck & Co., Inc. |
Somatostatin agonists
|
US6013652A
(en)
*
|
1997-12-04 |
2000-01-11 |
Merck & Co., Inc. |
Spiro-substituted azacycles as neurokinin antagonists
|
BR9906975A
(pt)
|
1998-01-16 |
2000-10-17 |
Novo Nordisk As |
Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero
|
CA2334551A1
(en)
*
|
1998-06-11 |
1999-12-16 |
Merck & Co., Inc. |
Spiropiperidine derivatives as melanocortin receptor agonists
|
US6294534B1
(en)
*
|
1998-06-11 |
2001-09-25 |
Merck & Co., Inc. |
Spiropiperidine derivatives as melanocortin receptor agonists
|
US6682908B1
(en)
|
1998-07-10 |
2004-01-27 |
Merck & Co., Inc. |
Mouse growth hormone secretagogue receptor
|
CA2333857A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
US6645726B1
(en)
|
1998-08-10 |
2003-11-11 |
Merck & Co., Inc. |
Canine growth hormone secretagogue receptor
|
US6639076B1
(en)
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6194402B1
(en)
|
1998-09-02 |
2001-02-27 |
Merck & Co., Inc. |
Enhancement of return to independent living status with a growth hormone secretagogue
|
US6380184B1
(en)
|
1998-10-28 |
2002-04-30 |
Bristol-Myers Squibb Co. |
Benzoazepines and analogs thereof useful as growth hormone secretagogues
|
CA2362290A1
(en)
|
1999-02-18 |
2000-08-24 |
Kaken Pharmaceutical Co., Ltd. |
Novel amide derivatives as growth hormone secretagogues
|
US6828331B1
(en)
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6541634B2
(en)
|
1999-02-26 |
2003-04-01 |
Pfizer Inc. |
Process for preparing growth hormone secretagogues
|
US6525203B1
(en)
|
1999-03-12 |
2003-02-25 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US6518292B1
(en)
|
1999-03-12 |
2003-02-11 |
Bristol-Myers Squibb Co. |
Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
|
EP1187614A4
(en)
|
1999-06-04 |
2005-06-22 |
Merck & Co Inc |
SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
|
US20040266802A1
(en)
*
|
1999-06-07 |
2004-12-30 |
Alain Calvet |
Tricyclic analgesics
|
ES2219368T3
(es)
*
|
1999-07-13 |
2004-12-01 |
MERCK & CO., INC. |
Amidoespiropiperidinas que promueven la liberacion de la hormona de crecimiento.
|
WO2001060796A1
(en)
*
|
2000-02-18 |
2001-08-23 |
Meiji Seika Kaisha, Ltd. |
PHENOXYALKYLAMINE DERIVATIVES USEFUL AS OPIOID δ RECEPTOR AGONISTS
|
EP1268449A4
(en)
|
2000-03-23 |
2004-09-15 |
Merck & Co Inc |
SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
|
JP2003527444A
(ja)
|
2000-03-23 |
2003-09-16 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
|
ES2252230T3
(es)
|
2000-05-11 |
2006-05-16 |
Bristol-Myers Squibb Company |
Analogos de tetrahidroisoquinolina utiles como secretores de la hormona del crecimiento.
|
ATE446758T1
(de)
|
2000-05-31 |
2009-11-15 |
Pfizer Prod Inc |
Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
|
JP2004506687A
(ja)
|
2000-08-23 |
2004-03-04 |
メルク エンド カムパニー インコーポレーテッド |
メラノコルチン受容体作働薬としての置換ピペリジン類
|
AP1699A
(en)
*
|
2001-03-21 |
2006-12-26 |
Warner Lambert Co |
New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
|
ES2316559T3
(es)
|
2001-04-18 |
2009-04-16 |
Euro-Celtique S.A. |
Compuestos espiroindeno y espiroindano.
|
US6911447B2
(en)
*
|
2001-04-25 |
2005-06-28 |
The Procter & Gamble Company |
Melanocortin receptor ligands
|
WO2002094825A1
(fr)
*
|
2001-05-22 |
2002-11-28 |
Banyu Pharmaceutical Co., Ltd. |
Nouveau derive de spiropiperidine
|
US7125840B2
(en)
*
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
AU2002357692A1
(en)
|
2001-11-09 |
2003-05-26 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
|
US20060167268A1
(en)
*
|
2002-04-09 |
2006-07-27 |
Eli Lilly And Company, Patent Division, |
Growth hormone secretagogues
|
WO2003087069A2
(en)
*
|
2002-04-09 |
2003-10-23 |
Eli Lilly And Company |
Dipeptidic growth hormone secretagogues
|
US20040010010A1
(en)
*
|
2002-04-30 |
2004-01-15 |
Ebetino Frank Hallock |
Melanocortin receptor ligands
|
US7026335B2
(en)
*
|
2002-04-30 |
2006-04-11 |
The Procter & Gamble Co. |
Melanocortin receptor ligands
|
GB0213715D0
(en)
*
|
2002-06-14 |
2002-07-24 |
Syngenta Ltd |
Chemical compounds
|
TW200504033A
(en)
*
|
2002-10-23 |
2005-02-01 |
Procter & Gamble |
Melanocortin receptor ligands
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
CN1297557C
(zh)
*
|
2003-04-10 |
2007-01-31 |
上海药明康德新药开发有限公司 |
螺环类模板化合物的制备
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
WO2005027913A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
|
WO2005042003A1
(en)
*
|
2003-10-24 |
2005-05-12 |
Merck & Co., Inc. |
Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue
|
EP1682136A4
(en)
*
|
2003-11-04 |
2009-06-03 |
Elixir Pharmaceuticals Inc |
THERAPEUTIC COMPOUNDS AND CORRESPONDING USES THEREOF
|
GB0328906D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
GB0328908D0
(en)
*
|
2003-12-12 |
2004-01-14 |
Syngenta Participations Ag |
Chemical compounds
|
CA2561801A1
(en)
*
|
2004-04-02 |
2005-10-20 |
Elixir Pharmaceuticals, Inc. |
Sulfonamides and uses thereof
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
AU2005277389A1
(en)
|
2004-08-18 |
2006-03-02 |
Elixir Pharmaceuticals, Inc. |
Growth-hormone secretagogues
|
US7786141B2
(en)
*
|
2004-08-19 |
2010-08-31 |
Vertex Pharmaceuticals Incorporated |
Dihydrospiroindene modulators of muscarinic receptors
|
EP1781288A2
(en)
*
|
2004-08-19 |
2007-05-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
KR101285483B1
(ko)
*
|
2004-10-28 |
2013-07-12 |
상꾜 가부시키가이샤 |
광학 활성 4,4-2치환 옥사졸리딘 유도체와 그 제조 방법
|
RU2007124373A
(ru)
*
|
2004-11-29 |
2009-01-10 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы мускариновых рецептеров
|
US8293900B2
(en)
|
2005-09-29 |
2012-10-23 |
Merck Sharp & Dohme Corp |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
EP1973543A2
(en)
*
|
2005-12-22 |
2008-10-01 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US8263605B2
(en)
*
|
2006-02-22 |
2012-09-11 |
Vertex Pharmaceutical Incorporated |
Modulators of muscarinic receptors
|
RU2008137593A
(ru)
*
|
2006-02-22 |
2010-03-27 |
Вертекс Фармасьютикалз Инкорпорейтед (Us) |
Модуляторы мускариновых рецепторов
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
CN101092396B
(zh)
*
|
2006-06-20 |
2010-09-15 |
上海药明康德新药开发有限公司 |
螺[1,3-二氢茚-4'-哌啶-1-羧酸]模板化合物的制备方法
|
CN101500565A
(zh)
*
|
2006-06-29 |
2009-08-05 |
弗特克斯药品有限公司 |
毒蕈碱性受体的调节剂
|
CA2660903A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
AU2007284350A1
(en)
*
|
2006-08-18 |
2008-02-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
CA2664113C
(en)
|
2006-09-22 |
2013-05-28 |
Merck & Co., Inc. |
Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
|
EP2120569B1
(en)
*
|
2007-01-12 |
2013-08-14 |
Merck Sharp & Dohme Corp. |
Spirochromanon derivatives
|
EP2118080B1
(en)
|
2007-02-09 |
2016-08-31 |
Ocera Therapeutics, Inc. |
Macrocyclic ghrelin receptor modulators and methods of using the same
|
EP2155769B1
(en)
|
2007-05-04 |
2012-06-27 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
Tissue degeneration protection
|
CA2688161C
(en)
|
2007-06-04 |
2020-10-20 |
Kunwar Shailubhai |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
CA2700724A1
(en)
*
|
2007-10-03 |
2009-04-09 |
Vertex Pharmaceuticals Incorporated |
Modulators of muscarinic receptors
|
US20100280049A1
(en)
*
|
2007-11-06 |
2010-11-04 |
Amira Pharmaceuticals, Inc. |
Antagonists of pgd2 receptors
|
ES2522968T3
(es)
|
2008-06-04 |
2014-11-19 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
MX2011004551A
(es)
|
2008-10-30 |
2011-05-25 |
Merck Sharp & Dohme |
Antagonistas del receptor de orexina de isonicotinamida.
|
WO2012012843A1
(en)
*
|
2010-07-28 |
2012-02-02 |
The University Of Queensland |
Modulators of protease activated receptors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8546416B2
(en)
|
2011-05-27 |
2013-10-01 |
Novartis Ag |
3-spirocyclic piperidine derivatives as ghrelin receptor agonists
|
WO2013013273A1
(en)
*
|
2011-07-28 |
2013-01-31 |
The University Of Queensland |
Modulators of protease activated receptors
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2013190520A2
(en)
|
2012-06-22 |
2013-12-27 |
The General Hospital Corporation |
Gh-releasing agents in the treatment of vascular stenosis and associated conditions
|
WO2014065341A1
(ja)
|
2012-10-24 |
2014-05-01 |
第一三共株式会社 |
筋萎縮性側索硬化症治療剤
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
CA2926685A1
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
WO2015164308A1
(en)
*
|
2014-04-22 |
2015-10-29 |
Merck Sharp & Dohme Corp. |
FACTOR XIa INHIBITORS
|
CN106572997A
(zh)
|
2014-05-30 |
2017-04-19 |
辉瑞公司 |
作为选择性雄激素受体调节剂的腈衍生物
|
WO2017075535A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
AU2018291163A1
(en)
*
|
2017-06-30 |
2020-01-23 |
Quixgen, Inc. |
Novel spirolactone compounds
|
BR112020016256A2
(pt)
|
2018-02-21 |
2020-12-15 |
AI Therapeutics, Inc. |
Terapia de combinação com apilimod e agentes gluta-matérgicos
|
US11098029B2
(en)
|
2019-02-13 |
2021-08-24 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
EP4010314B1
(en)
|
2019-08-08 |
2024-02-28 |
Merck Sharp & Dohme LLC |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
AU2021329805B2
(en)
|
2020-08-18 |
2024-02-29 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|